MIRA INFORM REPORT

 

 

Report Date :

12.03.2014

 

IDENTIFICATION DETAILS

 

Name :

ALEMBIC PHARMACEUTICALS LIMITED (w.e.f. 12.03.2011)

 

 

Formerly Known As :

ALEMBIC PHARMA LIMITED

 

 

Registered Office :

Alembic Road, Vadodara-390002, Gujarat

 

 

Country :

India

 

 

Financials (as on) :

31.03.2013

 

 

Date of Incorporation :

16.06.2010

 

 

Com. Reg. No.:

061123

 

 

Capital Investment / Paid-up Capital :

Rs.377.032 Millions

 

 

CIN No.:

[Company Identification No.]

L24230GJ2010PLC061123

 

 

TAN No.:

[Tax Deduction & Collection Account No.]

BRDA03515B

 

 

PAN No.:

[Permanent Account No.]

AAICA5591M

 

 

Legal Form :

A Public Limited Liability Company. The Company’s Shares are Listed on The Stock Exchanges.

 

 

Line of Business :

Manufacturer of Pharmaceutical Products.

 

 

No. of Employees :

Information declined by the management 

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba (55)

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Maximum Credit Limit :

USD 18000000

 

 

Status :

Good

 

 

Payment Behaviour :

Regular

 

 

Litigation :

Clear

 

 

Comments :

Subject is a well-established and reputed company having a good track record. The operations of the company are carried out efficiently.

 

The pharmaceutical undertaking of the ‘Alembic Limited’ has been demerged and the same is transferred to the company with effect from 1st April 2010.

 

Financial position of the company appears to be sound and healthy. Directors are reported as well experienced and knowledgeable businessmen.

 

Trade relations are reported as trustworthy. Business is active. Payment terms are reported as regular and as per commitments.

 

The company can be considered good for business dealings at usual trade terms and conditions.

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – December 1, 2013

 

Country Name

Previous Rating

(30.09.2013)

Current Rating

(01.12.2013)

India

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

INDIAN ECONOMIC OVERVIEW

 

State-run banks hired nearly 300000 personnel including more than 94000 officers in the last four years, according to the Indian Banks Association. A study by trade lobby Assocham in September 2013 indicated that banks would need 800000 people in the next six years. It estimated that state-run lenders alone would hire 50000 people in 2013/14.

 

The Competition Commission of India plans to issue final orders within a broad time-frame of one year in matters where it decides to carry out detailed investigations. The number of complaints received by the watchdog which keeps tabs on unfair trade practices in the marketplace.

 

The government has detected custom tax evasion totaling around Rs 37920 mn in 14 states until December. Maharashtra topped the list of Rs 14190 mn followed by Andhra Pradesh at Rs 8140 mn, Gujarat Rs 5240 mn, Karnataka Rs 1670 mn and Tamilnadu Rs 1610 mn.

 

Connaught Place in New Delhi slipped four notches to become the world’s eighth most expensive office locations. London’s West End is the world’s most expensive office market.

 

There are 4.072 mn number of high value spenders under the scanner of the income tax department. The income tax department has information that they have made cash deposits announcing to Rs 1 mn or more in their savings bank accounts in the current financial year. It plans to check potential evasion before the closing of the financial year on March 31.

 

Estimated pharmaceutical sales in the country for 2016 is $ 27 bn. It is 14.4 per cent higher than a year ago. The life sciences and health care industry is up against challenges such as quality management, says a recent Deloitte report.

 

EXTERNAL AGENCY RATING

 

Rating Agency Name

CRISIL

Rating

Long term rating: AA

Rating Explanation

Have degree of safety and carry very low credit risk.

Date

04.10.2013

 

Rating Agency Name

CRISIL

Rating

Short term rating: A1+

Rating Explanation

Have very strong degree of safety and carry lowest credit risk.

Date

04.10.2013

 

 

RBI DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available RBI Defaulters’ list.

 

 

EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available EPF (Employee Provident Fund) Defaulters’ list as of 31-03-2012.

 

 

INFORMATION DECLINED

 

MANAGEMENT NON – COOPERATIVE (91-265-2280550)

 

LOCATIONS

 

Registered Office / Factory 1 :

Alembic Road, Vadodara-390002, Gujarat, India

Tel. No.:

91-265-2280550/2280880

Fax No.:

91-265-2281508/22847283053333/300

E-Mail :

infoal@alembic.co.in

apl.investors@alembic.co.in

chirag.shukla@alembic.co.in

Website :

www.alembic-india.com

 

 

Marketing Office:

2nd Floor , Prime Corporate Park, Behind ITC Grand Maratha Sheraton, Sahar Road, Andheri (E), Mumbai - 400099, Maharashtra, India

Tel. No.:

91 22 30611698

Fax No.:

91 22 30611682

 

 

Factory 2 :

Plot No.21/22, EPIP-Phase-I, Jhamajri, Baddi, Tehsil – Nalagarh, Solan – 173205, Himachal Pradesh, India

 

 

Factory 3 :

Village Karakhadi, Taluka Padra, District Vadodara, Gujarat, India

 

 

Factory 4 :

Panelav, Tal. Halol, District Panchmahal-389350, Gujarat, India

 

 

DIRECTORS

 

As on 31.03.2013

 

Name :

Mr. Chirayu Ramanbhai Amin

Designation :

Chairman and Managing Director

Address :

F 10/195, Race Course Circle, Gorti Road, Vadodara – 390007, Gujarat, India 

Date of Birth/Age :

04.12.1946

 

 

Name :

Mr. Krishnapuram Ramanathan

Designation :

Director

Address :

Srinidhi Bunglow, No. 1, Octroi Naka, Gorti Road, Vadodara – 390007, Gujarat, India

Date of Birth/Age :

15.05.1939

 

 

Name :

Mr. Rajkumar Shreeram Baheti

Designation :

Director and President-Finance

Address :

Flat No.402, Samprat Residency, 52, Alkapuri Society, Alkapuri, Vadodara – 390007, Gujarat, India

Date of Birth/Age :

24.10.1959

 

 

Name :

Mr. Pranav Natverlal Parikh

Designation :

Director

Address :

18 A, Manek, LD Ruparel Marg, Malbar hill, Mumbai – 400006, Maharashtra, India  

Date of Birth/Age :

18.02.1943

 

 

Name :

Mr. Paresh Saraiya

Designation :

Director

 

 

Name :

Mr. Pranav Amin

Designation :

Director and President-International Business

 

 

Name :

Mr. Milin Mehta

Designation :

Director

 

 

Name :

Mr. Shaunak Amin

Designation :

Director & President-Branded Formulations Business

(w.e.f. 2nd May, 2013)

 

 

KEY EXECUTIVES

 

Name :

Mr. Rajkumar Shreeram Baheti

Designation :

Company Secretary

 

 

MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN

 

As on 31.12.2013

 

Category of Shareholder

Total No. of Shares

Total Shareholding as a % of Total No. of Shares

(A) Shareholding of Promoter and Promoter Group

 

 

http://www.bseindia.com/include/images/clear.gif(1) Indian

 

 

http://www.bseindia.com/include/images/clear.gifIndividuals / Hindu Undivided Family

13402430

7.11

http://www.bseindia.com/include/images/clear.gifBodies Corporate

126336190

67.02

http://www.bseindia.com/include/images/clear.gifSub Total

139738620

74.13

http://www.bseindia.com/include/images/clear.gif(2) Foreign

 

 

Total shareholding of Promoter and Promoter Group (A)

139738620

74.13

(B) Public Shareholding

 

 

http://www.bseindia.com/include/images/clear.gif(1) Institutions

 

 

http://www.bseindia.com/include/images/clear.gifMutual Funds / UTI

1867156

0.99

http://www.bseindia.com/include/images/clear.gifFinancial Institutions / Banks

884166

0.47

http://www.bseindia.com/include/images/clear.gifForeign Institutional Investors

16387098

8.69

http://www.bseindia.com/include/images/clear.gifAny Others (Specify)

3600

0.00

http://www.bseindia.com/include/images/clear.gifOverseas Corporate Bodies

750

0.00

http://www.bseindia.com/include/images/clear.gifEmployee Welfare Fund

2850

0.00

http://www.bseindia.com/include/images/clear.gifSub Total

19142020

10.15

http://www.bseindia.com/include/images/clear.gif(2) Non-Institutions

 

 

http://www.bseindia.com/include/images/clear.gifBodies Corporate

1752623

0.93

http://www.bseindia.com/include/images/clear.gifIndividuals

 

 

http://www.bseindia.com/include/images/clear.gifIndividual shareholders holding nominal share capital up to Rs. 0.100 Million

21126874

11.21

http://www.bseindia.com/include/images/clear.gifIndividual shareholders holding nominal share capital in excess of Rs. 0.100 Million

5955894

3.16

http://www.bseindia.com/include/images/clear.gifAny Others (Specify)

799883

0.42

http://www.bseindia.com/include/images/clear.gifClearing Members

231310

0.12

http://www.bseindia.com/include/images/clear.gifTrusts

10280

0.01

http://www.bseindia.com/include/images/clear.gifNon Resident Indians

558293

0.30

http://www.bseindia.com/include/images/clear.gifSub Total

29635274

15.72

Total Public shareholding (B)

48777294

25.87

Total (A)+(B)

188515914

100.00

(C) Shares held by Custodians and against which Depository Receipts have been issued

0

0.00

http://www.bseindia.com/include/images/clear.gif(1) Promoter and Promoter Group

0

0.00

http://www.bseindia.com/include/images/clear.gif(2) Public

0

0.00

http://www.bseindia.com/include/images/clear.gifSub Total

0

0.00

Total (A)+(B)+(C)

188515914

0.00

 

 

BUSINESS DETAILS

 

Line of Business :

Manufacturer of Pharmaceutical Products.

 

PRODUCTION STATUS [AS ON 31.03.2011]

 

Particulars

Unit

Installed Capacity

*Actual Production

Bulk Drugs and Chemical and Intermediates

MMU/MT

#

673.454

Formulations:

 

 

 

Tablets and Capsules

Million Nos.

4653.000

3343.895

Injectables

Million Nos.

-***

84.747

Oral Preparation and Ointments

MT

10182.616

9272.980

 

NOTE:

 

* Including production on loan licence basis, captive consumption, samples and purchases of finished products.

 

# Installed Capacity: The Installed capacity is flexible as the plant is versatile; enabling the Company to produce in different capacity and therefore, it varies depending upon the product programme.

 

*** Entire production is on loan license basis.

 

 

 

GENERAL INFORMATION

 

No. of Employees :

Information declined by the management 

 

 

Bankers :

  • AXIS Bank Limited
  • Bank of Baroda
  • HDFC Bank Limited
  • IDBI Bank Limited
  • Standard Chartered Bank
  • The Royal Bank of Scotland N.V

 

 

Facilities :

Secured Loan

31.03.2013

(Rs. in Millions)

31.03.2012

(Rs. in Millions)

Long-term Borrowings

 

 

Term loans

 

Foreign Currency loan from Banks - @ Coupon of LIBOR plus 1.50% p.a. plus proportionate front end fees Secured against fi rst hypothecation charge on all movable plant and machinery ranking pari passu with other lenders Redeemable in 15 equal quarterly installments of USD 1 MN starting from May-13

597.080

763.200

Short-term borrowings

 

 

Working Capital facilities

104.065

235.744

Total

701.145

998.944

 

 

 

Banking Relations :

 

 

 

Auditors :

 

Name :

K.S. Aiyar and Company

Chartered Accountants

Address :

Laxmi Estate No. F-07/08, Shakti Mills Lane, Off Dr. E. Moses Road, Mahalaxmi, Mumbai-400011, Maharashtra, India

Tel No.:

91-22-24932502/66551770

Fax No.:

91-22-66551774

Email:

mail@ksaiyar.com

Website:

www.ksaiyar.com

 

 

Subsidiary and Fellow Subsidiary::

  • Alembic Global Holding SA (Subsidiary of Alembic Pharmaceuticals Limited)
  • Alembic Pharmaceuticals Australia Pty Limited (Subsidiary of Alembic Global Holding SA.)
  • Alembic Pharmaceuticals Europe Limited (Subsidiary of Alembic Global Holding SA.)
  • Alnova Pharmaceuticals SA (Subsidiary of Alembic Global Holding SA.)
  • Alembic Pharmaceuticals Inc. (Subsidiary of Alembic Global Holding SA.)

 

 

Associate Companies:

  • Alembic Limited
  • Paushak Limited
  • Whitefi eld Chemtech Private Limited
  • Sierra Investments Limited
  • Nirayu Private Limited
  • Viramya Packlight Limited
  • Quick Flight Private Limited
  • Incozen Therapeutics Private Limited
  • Shreno Limited
  • Rhizen Pharmaceuticals SA

 

 

CAPITAL STRUCTURE

 

As on 31.03.2013

 

Authorised Capital :

No. of Shares

Type

Value

Amount

200000000

Equity Shares

Rs.2/- each

Rs.400.000 Millions

 

Issued, Subscribed & Paid-up Capital :

No. of Shares

Type

Value

Amount

188515914

Equity Shares

Rs.2/- each

Rs.377.032 Millions

 

Note:

 

Reconciliation of the number of shares outstanding at the beginning and at the end of the reporting period ;

 

 

As on 31.03.2013

 

 

No. of Shares

 

Rs. in Millions

At the beginning of the period

18,85,15,914

377.032

Issued during the period

--

--

Outstanding at the end of the period

118,85,15,914

377.032

 

The rights, preferences and restrictions including restrictions on the distribution of dividends and the repayment of capital;

 

The company is having only one class of shares i.e Equity carrying a nominal value of H 2/- per share

 

Every holder of the equity share of the Company is entitled to one vote per share held In the event of liquidation of the Company, the equity shareholders will be entitled to receive remaining assets of the Company after the distribution / repayment of all creditors. The distribution to the equity shareholders will be in proportion of the number of shares held by each shareholder

 

The Company declares and pays dividend on the equity shares in Indian Rupees. Dividend proposed by the Board of Directors is subject to approval of the shareholders at the ensuing Annual General Meeting.

 

During the year ended 31st March, 2013 an amount of H 2.50 of dividend per equity share was proposed for the equity shareholders

 

(PY H 1.40 per equity share)

 

Shares in the company held by each shareholder holding more than 5 percent shares specifying the number of shares held

 

 

As on 31.03.2013

 

 

No. of Shares

 

% of Held

Alembic Limited

55000000

29.18%

Shreno Limited

18368780

9.74%

Sierra Investments Limited

17167670

9.11%

Whitefield Chemtech Limited

18285230

9.70%

Nirayu Private Limited

16213755

8.60%


 

FINANCIAL DATA

[all figures are in Rupees Millions]

 

ABRIDGED BALANCE SHEET

 

SOURCES OF FUNDS

 

31.03.2013

31.03.2012

31.03.2011

I.              EQUITY AND LIABILITIES

 

 

 

(1)Shareholders' Funds

 

 

 

(a) Share Capital

377.032

377.032

377.032

(b) Reserves & Surplus

4220.606

3231.592

2385.064

(c) Money received against share warrants

0.000

0.000

0.000

 

 

 

 

(2) Share Application money pending allotment

0.000

0.000

0.000

Total Shareholders’ Funds (1) + (2)

4597.638

3608.624

2762.096

 

 

 

 

(3) Non-Current Liabilities

 

 

 

(a) long-term borrowings

705.347

948.567

1284.837

(b) Deferred tax liabilities (Net)

138.969

95.290

53.746

(c) Other long term liabilities

127.607

122.907

118.417

(d) long-term provisions

60.606

53.904

51.016

Total Non-current Liabilities (3)

1032.529

1220.668

1508.016

 

 

 

 

(4) Current Liabilities

 

 

 

(a) Short term borrowings

701.145

1384.349

1462.768

(b) Trade payables

2342.456

1819.275

1317.541

(c) Other current liabilities

692.529

1516.044

849.005

(d) Short-term provisions

620.550

356.634

259.085

Total Current Liabilities (4)

4356.680

5076.302

3888.399

 

 

 

 

TOTAL

9986.847

9905.594

8158.511

 

 

 

 

II.          ASSETS

 

 

 

(1) Non-current assets

 

 

 

(a) Fixed Assets

 

 

 

(i) Tangible assets

3442.215

2678.186

2719.854

(ii) Intangible Assets

0.000

0.000

0.000

(iii) Capital work-in-progress

322.618

582.397

265.030

(iv) Intangible assets under development

0.000

0.000

0.000

(b) Non-current Investments

33.542

33.542

33.542

(c) Deferred tax assets (net)

0.000

0.000

0.000

(d)  Long-term Loan and Advances

358.788

349.913

65.447

(e) Other Non-current assets

0.000

0.000

0.000

Total Non-Current Assets

4157.163

3644.038

3083.873

 

 

 

 

(2) Current assets

 

 

 

(a) Current investments

0.000

0.000

0.000

(b) Inventories

2668.333

2587.415

2192.319

(c) Trade receivables

2323.830

1868.328

2019.739

(d) Cash and cash equivalents

42.497

257.339

12.880

(e) Short-term loans and advances

795.024

1548.474

849.700

(f) Other current assets

0.000

0.000

0.000

Total Current Assets

5829.684

6261.556

5074.638

 

 

 

 

TOTAL

9986.847

9905.594

8158.511

 

PROFIT & LOSS ACCOUNT

 

 

PARTICULARS

 

31.03.2013

31.03.2012

31.03.2011

 

SALES

 

 

 

 

 

Income

14926.383

13743.043

11649.258

 

 

Other Income

39.320

14.207

0.833

 

 

TOTAL                                     (A)

14965.703

13757.250

11650.091

 

 

 

 

 

Less

EXPENSES

 

 

 

 

 

Cost of Materials Consumed

4702.977

5282.376

4349.443

 

 

Purchase of Finished Goods

1655.905

1677.929

1285.731

 

 

Changes in Inventories of Finished Goods and Work in Process

213.401

(644.398)

(47.219)

 

 

Employee Benefit Expenses

1937.897

1684.582

1492.143

 

 

Research and Development Expenses

736.328

585.821

471.318

 

 

Other Expenses

3242.227

3070.835

2540.573

 

 

TOTAL                                     (B)

12488.735

11657.145

10091.989

 

 

 

 

 

Less

PROFIT BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION (A-B)     (C)

2476.968

2100.105

1558.102

 

 

 

 

 

Less

FINANCIAL EXPENSES                                    (D)

145.743

262.134

238.887

 

 

 

 

 

 

PROFIT BEFORE TAX, DEPRECIATION AND AMORTISATION (C-D)                                       (E)

2331.225

1837.971

1319.215

 

 

 

 

 

Less/ Add

DEPRECIATION/ AMORTISATION                     (F)

349.646

336.458

295.883

 

 

 

 

 

 

PROFIT BEFORE TAX (E-F)                              (G)

1981.579

1501.513

1023.332

 

 

 

 

 

Less

TAX                                                                  (H)

407.143

296.162

208.261

 

 

 

 

 

 

PROFIT AFTER TAX (G-H)                                (I)

1574.436

1205.351

815.071

 

 

 

 

 

Add

PREVIOUS YEARS’ BALANCE BROUGHT FORWARD

536.300

216.800

815.000

 

 

 

 

 

 

APPROPRIATIONS

 

 

 

 

 

Debenture Redemption Reserve

0.000

79.200

79.200

 

 

Provision for Dividend - Equity Shares

471.300

263.900

188.500

 

 

Provision for Corporate Dividend tax

80.100

42.800

30.500

 

 

Transfer to General Reserve

800.000

500.000

300.000

 

BALANCE CARRIED TO THE B/S

759.400

536.3000

216.800

 

 

 

 

 

 

EARNINGS IN FOREIGN CURRENCY

 

 

 

 

 

Export Earnings

4650.158

4679.560

3604.849

 

 

Royalty

152.168

116.044

4.738

 

TOTAL EARNINGS

4802.326

4795.604

3609.587

 

 

 

 

 

 

IMPORTS

 

 

 

 

 

Raw Materials

1554.182

1863.148

1788.218

 

 

Packing Material , Components and Spare parts

90.897

21.803

43.514

 

TOTAL IMPORTS

1645.079

1884.951

1831.732

 

 

 

 

 

 

Earnings Per Share (Rs.)

8.35

6.39

4.32

 

 

QUARTERLY RESULTS

 

PARTICULARS

 

30.06.2013

Type

1st Quarter

Net Sales

4268.400

Total Expenditure

3525.500

PBIDT (Excl OI)

742.900

Other Income

0.200

Operating Profit

743.100

Interest

14.700

Exceptional Items

0.000

PBDT

728.400

Depreciation

95.300

Profit Before Tax

633.100

Tax

138.400

Provisions and contingencies

0.000

Profit After Tax

494.700

Extraordinary Items

0.000

Prior Period Expenses

0.000

Other Adjustments

0.000

Net Profit

494.700

 

KEY RATIOS

 

PARTICULARS

 

 

31.03.2013

31.03.2012

31.03.2011

PAT / Total Income

(%)

10.52

8.76

7.00

 

 

 

 

 

Net Profit Margin

(PBT/Sales)

(%)

12.85

10.93

8.78

 

 

 

 

 

Return on Total Assets

(PBT/Total Assets}

(%)

20.57

16.16

13.02

 

 

 

 

 

Return on Investment (ROI)

(PBT/Networth)

 

0.43

0.42

0.37

 

 

 

 

 

Debt Equity Ratio

(Total Debt /Networth)

 

0.31

0.65

0.99

 

 

 

 

 

Current Ratio

(Current Asset/Current Liability)

 

1.34

1.23

1.31

 

 

FINANCIAL ANALYSIS

[all figures are in Rupees Millions]

 

DEBT EQUITY RATIO

 

Particular

31.03.2011

31.03.2012

31.03.2013

 

(Rs. In Millions)

(Rs. In Millions)

(Rs. In Millions)

Share Capital

377.032

377.032

377.032

Reserves & Surplus

2385.064

3231.592

4220.606

Net worth

2,762.096

3,608.624

4,597.638

 

 

 

 

long-term borrowings

1284.837

948.567

705.347

Short term borrowings

1462.768

1384.349

701.145

Total borrowings

2,747.605

2,332.916

1,406.492

Debt/Equity ratio

0.995

0.646

0.306

 

 

YEAR-ON-YEAR GROWTH

 

Year on Year Growth

31.03.2011

31.03.2012

31.03.2013

 

(Rs. In Millions)

(Rs. In Millions)

(Rs. In Millions)

Sales

11649.258

13743.043

14926.383

 

 

17.974

8.610

 

 

NET PROFIT MARGIN

 

Net Profit Margin

31.03.2011

31.03.2012

31.03.2013

 

(Rs. In Millions)

(Rs. In Millions)

(Rs. In Millions)

Sales

11649.258

13743.043

14926.383

Profit

815.071

1205.351

1574.436

 

7.00%

8.77%

10.55%

 

 

LOCAL AGENCY FURTHER INFORMATION

 

 

Sr. No.

Check List by Info Agents

Available in Report (Yes / No)

1]

Year of Establishment

Yes

2]

Locality of the firm

Yes

3]

Constitutions of the firm

Yes

4]

Premises details

No

5]

Type of Business

Yes

6]

Line of Business

Yes

7]

Promoter's background

Yes

8]

No. of employees

No

9]

Name of person contacted

No

10]

Designation of contact person

No

11]

Turnover of firm for last three years

Yes

12]

Profitability for last three years

Yes

13]

Reasons for variation <> 20%

--

14]

Estimation for coming financial year

No

15]

Capital in the business

Yes

16]

Details of sister concerns

Yes

17]

Major suppliers

No

18]

Major customers

No

19]

Payments terms

No

20]

Export / Import details (if applicable)

No

21]

Market information

--

22]

Litigations that the firm / promoter involved in

--

23]

Banking Details

Yes

24]

Banking facility details

Yes

25]

Conduct of the banking account

--

26]

Buyer visit details

--

27]

Financials, if provided

Yes

28]

Incorporation details, if applicable

Yes

29]

Last accounts filed at ROC

Yes

30]

Major Shareholders, if available

Yes

31]

Date of Birth of Proprietor/Partner/Director, if available

Yes

32]

PAN of Proprietor/Partner/Director, if available

No

33]

Voter ID No of Proprietor/Partner/Director, if available

No

34]

External Agency Rating, if available

Yes

 

UNSECURED LOAN

 

PARTICULARS

31.03.2013

(Rs. in Millions)

31.03.2012

(Rs. in Millions)

Long-term Borrowings

 

 

Deposits

 

 

Deposits from Shareholders

41.930

15.930

Deposits from Public

Interest rate varying from 9% to 11% and maturity period is 12 / 24 / 36 months

66.337

169.152

Others

Repayable in 10 equal yearly installments of H2.8.500 Millions each commencing from Oct-2004. Interest rate 3%

0.000

0.285

Short-term borrowings

 

 

Others

varying Coupon repayable within 180 days with an option of roll over

597.080

898.605

Commercial Paper

Coupon of 10.20% repayable within 90 days

0.000

250.000

Total

705.347

1333.972

 

OPERATIONS:

 

The Company’s Standalone revenues from operations were H1, 4926.200 Millions for the year ended 31st March, 2013 as compared to H1, 3743.000 Millions for the previous year.

 

The standalone profit before Interest, Depreciation, Non-recurring Income and expenses and Taxes was H 2437.600 Millions for the year as compared to H 2085.900 Millions for the previous year.

 

During the year, the interest and financing cost was H 145.700 Millions as compared to H 262.100 Millions in previous year. The Company has registered consolidated revenues from operations of H 15203.400 Millions for the year as compared to H1, 4654.100 Millions for the previous year.

 

INDEX OF CHARGES

 

S.NO.

CHARGE ID

DATE OF CHARGE CREATION/MODIFICATION

CHARGE AMOUNT SECURED

CHARGE HOLDER

ADDRESS

SERVICE REQUEST NUMBER (SRN)

1

10323112

02/12/2011

780,000,000.00

DBS BANK LIMITED

UPPER GROUND FLOR, BIRLA TOWER,, 25 BARAKHAMBA RO
AD, NEW DELHI, DELHI - 110001, INDIA

B27859248

2

10296745

30/06/2011

2,420,000,000.00

BANK OF BARODA AND OTHER BANKS

FIRST FLOOR, BANK OF BARODA BUILDING, R. C. DUTT
ROAD, VADODARA, GUJARAT - 390007, INDIA

B16625071

 

 

UNAUDITED FINANCIAL RESULTS FOR THE PERIOD ENDED 31ST DECEMBER 2013

(Rs. in Millions)

 

Quarter Ended

Period Ended

Particulars

31.12.2013

30.09.2013

31.12.2013

 

(Unaudited)

(Unaudited)

(Unaudited)

PART- I

 

 

 

(a)   Net Sales / Income from Operations

 

 

 

Domestic

2749.200

2865.500

8054.700

Exports

2027.700

2000.200

5872.400

Total

4776.900

4865.700

13927.100

Less : Excise Duty

18.700

17.700

58.200

Net Sales / Income from Operations

4758.200

4848.000

13868.900

(b)   Other Operating Income

7.800

4.600

18.100

Total Income from Operations

4766.000

4852.600

13887.000

Expenses

 

 

 

(a)   Decrease/(increase) in stock in trade and work in progress

(242.400)

(74.400)

(447.200)

(b)   Consumption of Raw Materials & Packing Materials

1514.400

1376.400

4250.500

(c)   Purchase of traded goods

479.900

593.000

1567.900

(d)   Employees' Cost

620.200

593.100

1776.900

(e)   Research and Development Expense

272.700

312.100

791.700

(f)   Excise Duty

7.600

20.800

36.300

(g)   Other Expenditure

1081.800

1082.600

3187.200

Total Expenses

3734.200

3903.600

11163.300

Profit from Operations before Other Income, Interest, Depreciation & Exceptional Items

1031.800

949.000

2723.700

Other Income

2.000

2.000

4.200

Profit/(Loss) from Ordinary Activities before Interest,

1033.800

951.000

2727.900

Depreciation, & Exceptional Items

101.200

98.500

295.000

Depreciation Interest (Net)

34.800

25.700

75.200

Net Profit / (Loss) from Ordinary Activities before Tax

897.800

826.800

2357.700

Tax Expense

 

 

 

Less : Provision for Current Tax

188.200

173.900

494.800

Less /Add : Provision for Deferred Tax Liability/(Assets)

31.200

14.600

51.500

Net Profit / (Loss) from Ordinary Activities after Tax

678.400

638.300

1811.400

Paid up Equity Share Capital

377.000

377.000

377.000

( Face value of share Rs. 2/- )

 

 

 

Reserves excluding Revaluation Reserve

 

 

 

Basic & Diluted EPS (Not Annualised)

3.60

3.39

9.61

Debt Equity Ratio

 

 

 

PART- II

 

 

 

Particulars of Shareholding

 

 

 

Public Shareholding

 

 

 

- Number of Shares

48777294

48777294

48777294

- Percentage of Shareholding

25.87

25.87

25.87

Promoters and Promoter Group Shareholding

 

 

 

- Fully Non - Encumbered

 

 

 

- Number of Shares

139738620

139738620

139738620

- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)

100.00

100.00

100.00

- Percentage of Shares (as a % of the total share capital of the Company)

74.13

74.13

74.13

INVESTOR COMPLAINTS

Quarter Ended

31.12.2013

 

Pending at the beginning of the quarter

NIL

 

Received during the quarter

3

 

Disposed of during the quarter

3

 

Remaining unresolved at the end of the quarter

NIL

 

 

NOTE:

 

The above results, have been duly reviewed by Statutory Auditor, recommended by the Audit Committee and approved by the Board of Directors. However, the unaudited results of the Subsidiary included in above have not been reviewed by Statutory Auditor. The Company has opted to publish consolidated financial results, pursuant to option made available as per clause 41 of the listing Agreement.


The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Reporting (AS-17).


The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

 

CONTINGENT LIABILITIES:

 

(Rs. in millions)

PARTICULARS

31.03.2013

31.03.2012

 

 

 

i) Letter of credit, Guarantees and counter guarantees

192.170

133.425

ii) Liabilities Disputed in appeals

 

 

- Excise duty

75.983

74.522

- Sales Tax

38.393

32.452

- Income Tax

0.458

0.000

- Stamp Duty

50.119

50.119

iii) Claims against the company not acknowledged as debt

34.264

35.66

iv) Non fulfi lment of export obligation against advance licenc

2.373

14.500

v) Disputed liability in respect of Ministry of Industry, Department of Chemicals and

Petrochemicals in respect of price of Rifampicin allowed in formulations and landed cost of import.

3.493

3.493

 

FIXED ASSETS

 

  • Free Hold Land
  • Lease Hold Land
  • Buildings
  • Employees Quarters
  • Plant and Equipments
  • R and D Equipments
  • Furniture and Fixtures
  • Vehicles
  • Office Equipments

 

 


 

CMT REPORT (Corruption, Money Laundering & Terrorism]

 

The Public Notice information has been collected from various sources including but not limited to: The Courts, India Prisons Service, Interpol, etc.

 

1]         INFORMATION ON DESIGNATED PARTY

No exist designating subject or any of its beneficial owners, controlling shareholders or senior officers as terrorist or terrorist organization or whom notice had been received that all financial transactions involving their assets have been blocked or convicted, found guilty or against whom a judgement or order had been entered in a proceedings for violating money-laundering, anti-corruption or bribery or international economic or anti-terrorism sanction laws or whose assets were seized, blocked, frozen or ordered forfeited for violation of money laundering or international anti-terrorism laws.

 

2]         Court Declaration :

No exist to suggest that subject is or was the subject of any formal or informal allegations, prosecutions or other official proceeding for making any prohibited payments or other improper payments to government officials for engaging in prohibited transactions or with designated parties.

 

3]         Asset Declaration :

No records exist to suggest that the property or assets of the subject are derived from criminal conduct or a prohibited transaction.

 

4]         Record on Financial Crime :

            Charges or conviction registered against subject:                                                           None

 

5]         Records on Violation of Anti-Corruption Laws :

            Charges or investigation registered against subject:                                                        None

 

6]         Records on Int’l Anti-Money Laundering Laws/Standards :

            Charges or investigation registered against subject:                                                        None

 

7]         Criminal Records

No available information exist that suggest that subject or any of its principals have been formally charged or convicted by a competent governmental authority for any financial crime or under any formal investigation by a competent government authority for any violation of anti-corruption laws or international anti-money laundering laws or standard.

 

8]         Affiliation with Government :

No record exists to suggest that any director or indirect owners, controlling shareholders, director, officer or employee of the company is a government official or a family member or close business associate of a Government official.

 

9]         Compensation Package :

Our market survey revealed that the amount of compensation sought by the subject is fair and reasonable and comparable to compensation paid to others for similar services.

 

10]        Press Report :

            No press reports / filings exists on the subject.

 


 

CORPORATE GOVERNANCE

 

MIRA INFORM as part of its Due Diligence do provide comments on Corporate Governance to identify management and governance. These factors often have been predictive and in some cases have created vulnerabilities to credit deterioration.

 

Our Governance Assessment focuses principally on the interactions between a company’s management, its Board of Directors, Shareholders and other financial stakeholders.

 

 

CONTRAVENTION

 

Subject is not known to have contravened any existing local laws, regulations or policies that prohibit, restrict or otherwise affect the terms and conditions that could be included in the agreement with the subject.

 

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.60.70

UK Pound

1

Rs.100.97

Euro

1

Rs.84.16

 

 

INFORMATION DETAILS

 

Information Gathered by :

NYA

 

 

Report Prepared by :

KVT

 


 

SCORE & RATING EXPLANATIONS

 

SCORE FACTORS

 

RANGE

POINTS

HISTORY

1~10

3

PAID-UP CAPITAL

1~10

6

OPERATING SCALE

1~10

7

FINANCIAL CONDITION

 

 

--BUSINESS SCALE

1~10

7

--PROFITABILIRY

1~10

5

--LIQUIDITY

1~10

7

--LEVERAGE

1~10

6

--RESERVES

1~10

6

--CREDIT LINES

1~10

8

--MARGINS

-5~5

-

DEMERIT POINTS

 

 

--BANK CHARGES

YES/NO

YES

--LITIGATION

YES/NO

NO

--OTHER ADVERSE INFORMATION

YES/NO

NO

MERIT POINTS

 

 

--SOLE DISTRIBUTORSHIP

YES/NO

NO

--EXPORT ACTIVITIES

YES/NO

NO

--AFFILIATION

YES/NO

YES

--LISTED

YES/NO

YES

--OTHER MERIT FACTORS

YES/NO

YES

DEFAULTER

 

 

--RBI

YES/NO

NO

--EPF

YES/NO

NO

TOTAL

 

55

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

 


 

RATING EXPLANATIONS

 

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

NB

NEW BUSINESS

 

 

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.